Scarica l'app Stockscreener
15.25
0.28%
0.043
Dopo l'orario di chiusura:
15.90
0.65
+4.26%
Precedente Chiudi:
$15.21
Aprire:
$14.745
Volume 24 ore:
66,261
Relative Volume:
1.44
Capitalizzazione di mercato:
$31.78M
Reddito:
-
Utile/perdita netta:
$-3.34M
Rapporto P/E:
-5.6492
EPS:
-2.6995
Flusso di cassa netto:
$-10.54M
1 W Prestazione:
+21.81%
1M Prestazione:
+17.40%
6M Prestazione:
+23.23%
1 anno Prestazione:
+265.39%
Intervallo 1D:
$14.25
$15.91
Intervallo di 1 settimana:
$12.00
$15.91
Portata 52W:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
15.25 | 31.69M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Borsa (PLRZ) Ultime notizie
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com India
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Canada
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan
Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon receives US patent publication notice for nasal drug delivery platform - MSN
Polyrizon Ltd. Ordinary Shares (NASDAQ: PLRZ) Stock Price, News & Analysis - Kalkine
Polyrizon (PLRZ) Stock Price, News & Analysis - MarketBeat
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent - TipRanks
Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan
Polyrizon announces U.S. patent application publication - Investing.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - The Manila Times
Polyrizon patent published for nasal drug-delivery technology - Stock Titan
Polyrizon announces U.S. patent application publication By Investing.com - Investing.com UK
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon stock surges on human study for allergy blocker - Investing.com
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Australia
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com South Africa
Polyrizon Ltd Azioni (PLRZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Polyrizon Ltd Azioni (PLRZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):